Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13936MR)

This product GTTS-WQ13936MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13936MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ656MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ13938MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ166MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ7043MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ10777MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ8116MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ10940MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ5389MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD58-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW